Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
Sponsor

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Germany Steinbacher Hohl 2-26, Praunheim, 60488 Frankfurt, Germany

About the sponsor

Gastroesophageal adenocarcinoma, gastric cancer, and colorectal cancer are central areas of interest, alongside multiple biliary tract cancers and cholangiocarcinoma subtypes. The portfolio also includes hepatocellular carcinoma across intermediate, advanced, and unresectable disease settings.

  • Intrahepatic cholangiocarcinoma
  • Extrahepatic cholangiocarcinoma
  • Metastatic colorectal cancer
  • Advanced hepatocellular carcinoma
  • Esophagogastric adenocarcinoma

Research activity also covers biomarker-defined disease groups, including FGFR2-altered and HER2-positive tumors in the upper gastrointestinal tract.

About Specializations

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH runs clinical trials in conditions such as Cholangiocarcinoma, Gastrooesophageal cancer, Oesophageal adenocarcinoma, Hepatocellular carcinoma, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

31 clinical trials

Oesophageal adenocarcinoma

Recruiting

Durvalumab plus drug combination as total neoadjuvant therapy for patients with resectable gastroesophageal adenocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Diffuse large B-cell lymphoma refractory+1

Recruiting

Glofitamab plus drug combination for relapsed/refractory large B‑cell lymphoma in high‑risk second‑line patients eligible for CAR‑T therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Neuroendocrine carcinoma of the skin

Recruiting

A Study of Cemiplimab Given Before Surgery in Patients with Early Stage Merkel Cell Carcinoma of the Skin

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Oesophageal adenocarcinoma

Recruiting

Study of zanidatamab with drug combination for patients with HER2 and PD-L1 positive advanced gastroesophageal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Penile squamous cell carcinoma

Recruiting

Study of enfortumab vedotin and avelumab for patients with advanced or metastatic penile cancer that has spread or cannot be removed by surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Cholangiocarcinoma

Recruiting

Study of ivosidenib maintenance treatment in patients with IDH1-mutated cholangiocarcinoma after standard chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Colorectal cancer metastatic

Recruiting

Study on Fruquintinib and Tislelizumab for Patients with Metastatic Colorectal Cancer Without Liver Metastases

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Basal cell carcinoma

Recruiting

Evaluation of Cemiplimab Safety and Effectiveness as First Treatment for Advanced Basal Cell Carcinoma in Adult Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Hepatocellular carcinoma

Recruiting

Study on Atezolizumab and Bevacizumab for Patients with Intermediate-Stage Liver Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Cholangiocarcinoma

Recruiting

Study on Durvalumab, Cisplatin, and Gemcitabine for Patients with Extrahepatic Cholangiocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Hormone receptor positive breast cancer+1

Recruiting

Study on Stopping CDK4/6 Inhibitors in Patients with Metastatic HR Positive, HER2 Negative Breast Cancer Using Abemaciclib, Letrozole, and Fulvestrant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Gastrooesophageal cancer+1

Not yet recruiting

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan with Drug Combination for Patients with HER2+ Resectable Esophagogastric Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.